免疫细胞有效剂量作为不可切除III期NSCLC放化疗后度伐利尤单抗应答独立预测因素的多中心评估
多中心回顾性研究纳入251例不可切除III期NSCLC患者,评估EDRIC与放化疗后度伐利尤单抗巩固治疗预后的关系。
要点
- 低EDRIC的PFS获益限于PD-L1阳性患者。
核心结论
- 在不可切除III期NSCLC放化疗后接受度伐利尤单抗的患者中,较低EDRIC与更长PFS相关,且该效应限于PD-L1阳性肿瘤患者。
研究设计与样本
- 多中心回顾性研究,收集2017至2024年3家三级中心286例接受根治性放疗的不可切除III期NSCLC患者数据,最终251例纳入分析。
关键数值与推荐
- EDRIC基于平均心脏、肺、全身剂量及分次数计算,最佳cutoff为9.57 Gy。
临床怎么用
- EDRIC可作为放化疗后度伐利尤单抗巩固治疗患者的免疫剂量学参考指标,低EDRIC提示可能更长PFS,尤其PD-L1阳性者。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The effective dose to immune cells-radiotherapy course-adjusted (EDRIC) is a dosimetry-based metric that estimates radiation exposure to circulating immune cells during radiotherapy. Elevated EDRIC is linked to lymphopenia, immune dysfunction, and poor tumor control in unresectable non-small cell lung cancer (NSCLC) after chemoradiation. However, it is unclear if EDRIC directly correlates with clinical outcomes and particularly with durvalumab consolidation, or if confounding factors drive this association. This study examined whether EDRIC independently correlates with progression-free survival (PFS). METHODS AND MATERIALS: Data from 286 patients with unresectable stage III NSCLC treated with definitive-intent radiation therapy between 2017 and 2024 at 3 tertiary centers were collected. EDRIC was calculated using mean heart, lung, body doses, and the number of fractions. Maximally selected rank statistics identified the optimal EDRIC cutoff for PFS. Univariable and multivariable Cox regression models were used to assess the association between EDRIC and clinical outcomes. RESULTS: Following the exclusion of patients who did not meet the inclusion criteria, 251 patients remained in the final analysis dataset. Using a cutoff of 9.57 Gy, 53 patients were classified as having high EDRIC and 198 as low EDRIC. Patients with low EDRIC had significantly longer median PFS (23.7 vs 11.7 months; hazard ratios (HR) 0.56; 95% CI, 0.39-0.82; P = .003). In a multivariable analysis including EDRIC, PD-L1 (programmed death ligand-1) expression, N stage (N3 vs N0-2), and PTV (planning target volume), lower EDRIC remained directionally associated with longer PFS (low vs high HR = 0.67; 95% CI, 0.45-1.01; P = .053), PD-L1 positive status remained associated with longer PFS (vs PD-L1 negative: HR = 0.64; 95% CI, 0.44-0.94; P = .021), and N3 was directionally adverse (HR = 1.56; 95% CI, 0.99-2.46; P = .054). CONCLUSIONS: In patients receiving durvalumab after chemoradiation for unresectable stage III NSCLC, lower EDRIC was associated with longer PFS. This effect was limited to patients with positive PD-L1 tumors.
引用
- Averbuch I, Appel S, Blumenfeld P, et al. Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 41242399. doi:10.1016/j.ijrobp.2025.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。